Key result
Long-term high-dose growth hormone fails to alter LV dimensions in children with Noonan's syndrome.
Why the study?
The effects of long-term high-dose growth hormone treatment on left ventricular dimensions in children with Noonan's syndrome were not well established.
Does high-dose growth hormone treatment adversely affect left ventricular dimensions in children with Noonan's syndrome?
Does high-dose growth hormone treatment adversely affect left ventricular dimensions in children with Noonan's syndrome?
Long-term high-dose growth hormone treatment appears safe and does not cause adverse changes in left ventricular dimensions in children with Noonan's syndrome.
GH treatment shows no clinically significant LV effects in NS; level 5 evidence leaves open need for larger confirmatory trials.
OBJECTIVE: To study the effects of long-term growth hormone (GH) treatment on left ventricular (LV) dimensions in children with Noonan's syndrome (NS). METHODS: Echocardiographic measurements of LV dimensions were performed before and during GH treatment in 27 participants (21 boys, 6 girls) in a partly controlled 3-year trial of high-dose GH treatment (0.15 IU/kg/day). Nineteen children had a congenital heart defect, 1 of them had hypertrophic obstructive cardiomyopathy. In the first 3 years, the children were assigned to 1 of 2 groups: group A with discontinuation of GH treatment in the 3rd year, or group B without GH treatment in the 1st year. After the 3rd year, 12 of the 27 children were followed up for 2 additional years to evaluate the long-term effects of GH treatment on the heart. RESULTS: At baseline, LV internal diameters were smaller, while posterior wall thickness were thicker than normal. Over the 1st year, changes in LV dimensions were comparable between the 2 groups. No significant differences were found in LV dimensions between the situation at baseline and after 4 years of GH treatment. CONCLUSION: Long-term high-dose GH treatment does not have clinically significant adverse effects on LV dimensions in children with NS.
No takes yet. Share an insight, caveat, or question.
Noordam et al. (2001) studied Noonan's syndrome (n=27). Growth hormone (GH) treatment vs. Delayed treatment or treatment discontinuation was evaluated on Left ventricular (LV) dimensions. Long-term high-dose growth hormone treatment (0.15 IU/kg/day) did not significantly alter left ventricular dimensions compared to baseline after 4 years of treatment in children with Noonan's syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: